TY - BOOK AU - Swain, Sandra M TI - Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA SN - 1083-7159 PY - 2014/// KW - *Antineoplastic Combined Chemotherapy Protocols/ae [Adverse Effects] KW - *Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use] KW - *Breast Neoplasms/dt [Drug Therapy] KW - *Receptor, ErbB-2/me [Metabolism] KW - Adult KW - Aged KW - Aged, 80 and over KW - Antibodies, Monoclonal, Humanized/ad [Administration & Dosage] KW - Antibodies, Monoclonal, Humanized/ae [Adverse Effects] KW - Biomarkers, Pharmacological KW - Breast Neoplasms/en [Enzymology] KW - Double-Blind Method KW - Female KW - Humans KW - Middle Aged KW - Taxoids/ad [Administration & Dosage] KW - Taxoids/ae [Adverse Effects] KW - Treatment Outcome KW - Washington Cancer Institute N1 - Available online from MWHC library: 1996 - present N2 - CONCLUSION: Despite a higher proportion of docetaxel dose reductions in patients from Asia, survival benefits were comparable between regions. The benefit-risk profile of pertuzumab, trastuzumab, and docetaxel supports this regimen as the first-line therapy for patients with HER2-positive metastatic breast cancer from all geographic regions.Copyright ©AlphaMed Press; INTRODUCTION: We report detailed safety analyses by geographic region from the phase III study CLEOPATRA with pertuzumab, trastuzumab, and docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive first-line metastatic breast cancer; PATIENTS AND METHODS: Patients received pertuzumab/placebo at 840 mg in cycle 1 and 420 mg in subsequent cycles, and trastuzumab at 8 mg/kg in cycle 1 and 6 mg/kg in subsequent cycles; docetaxel was initiated at 75 mg/m(2). All study drugs were given intravenously, 3 times weekly; RESULTS: Docetaxel dose reductions below 75 mg/m(2) were more common in patients from Asia (47.0%) than other regions (13.4%); docetaxel dose escalations to 100 mg/m(2) were less frequent in Asia (2.4%) than other regions (18.7%). Rates of edema (26.1% and 5.4% for Asia and other regions, respectively), myalgia (42.3%, 14.7%), nail disorder (39.9%, 15.1%), febrile neutropenia (18.6%, 7.1%), upper respiratory tract infection (25.7%, 10.2%), decreased appetite (47.0%, 19.1%), and rash (44.3%, 22.0%) were at least twice as high in Asia as in other regions. Adverse events did not result in a reduction in the median number of study treatment cycles administered in patients from Asia. Efficacy analyses per region showed hazard ratios similar to those of the whole intention-to-treat (ITT) population for progression-free survival (ITT: 0.63; Asia: 0.68; other regions: 0.61) and overall survival (ITT: 0.66; Asia: 0.64; other regions: 0.66) UR - http://dx.doi.org/10.1634/theoncologist.2014-0033 ER -